FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367338083> ?p ?o ?g. }

• W4367338083 endingPage "9" @default.
• W4367338083 startingPage "1" @default.
• W4367338083 abstract "Aim & Objective: To compare the efficacy of letrozole and clomiphene citrate (CC) by using injection of Human placental extract (HPE) for ovulation induction in infertile women. Introduction: Human placental extract (HPE) is a product of aqueous extraction from the biochemically enriched fresh human placenta which contains nucleotides, amino acids, peptides and vitamins in natural form. It is available as 2 ml ampule. Each ml. is derived from 0.1 gm. of fresh human placenta. Injection of HPE is used in infertility treatment for its anti-inflammatory property, due to which tubal inflammation is decreased and tubal motility increases which is useful for fertility. This is the hypothetical theory behind use of Injection of HPE for infertility treatment in infertile women. Clomiphene citrate has been traditionally used as drug of the choice for treatment of women with infertility. In the last decade, an aromatase inhibitor, letrozole has emerged as an alternative ovulation induction (OI) agent in anovulatory women with polycystic ovarian syndrome. Letrozole has a definitive role in anovulatory women who have not responded to clomiphene citrate therapy and this is confirmed by literatures. Background: Anovulatory dysfunction is a common problem and is responsible for about 40% of female infertility and among causes; PCOS (polycystic ovarian syndrome) is the leading cause. HPE is a product of aqueous extraction from the biochemically enriched fresh human placenta which contains nucleotides, amino acids, peptides and vitamins in natural form. HPE injection- properties: • Specific anti – inflammatory • Tissue repair–wound healing • Immunomodulatory • Melanopoetic • Debridement action It is useful in ovulation induction among infertile women who are infertile due to pelvic inflammatory disease (PID) or due to polycystic ovary syndrome (PCOS) because of its anti-inflammatory property which leads to reduction in tubal inflammation and increased tubal motility. Clomiphene citrate is considered as the first line of treatment for anovulatory dysfunction for a various reason, however Clomiphene citrate has some drawbacks like multi-follicular ovulation and Peripheral anti-estrogenic effect are areas of concern and desire for an effective alternative is need of the hour. An aromatase inhibitor, letrozole, was introduced into infertility practice in the year 2000 and is regarded as a second line option, particularly in women with clomiphene resistance and it has found acceptance in various clinical situations and the indications for its use have expanded. Design: Randomized double blind study. Setting: Scientific Research Institute, Surendranagar, Gujarat, India and a private practice setting. Patients & Methods: The study included 100 women who presented with infertility and were having polycystic ovary syndrome (PCOS). The study participants were divided into 2 groups of 50 each. With these injections, 1 group was given clomiphene citrate (100 mg daily) and another group was given; letrozole (5 mg daily), started from day 3 to day 5 of the menstruation cycle and continued up to 5 consecutive days. Both the groups have received Estradiol Valerate 4 mg. on the 12th day of menstruation until 16th day of menstruation; with visits to determine ovulation and pregnancy, followed by tracking of pregnancies. Selected participants were of age between 20 to 39 years, had normal uterine cavity and had intercourse with male partner with a sperm concentration of at least 14 million per millilitre; and during the study the women and their partners agreed to have regular periodical intercourse with the intent of successful conception. The live birth of baby during the treatment period was the primary outcome. Second Outcome Measures: Follicular growth, endometrial thickness, pregnancy outcome. Results: Women who received Letrozole had more cumulative live births than those women who had received Clomiphene Citrate, (38 out of 50 [76%] vs. 29 out of 50 [58%]) after giving Injection of HPE with these ovulation induction drugs, without significant differences in overall congenital anomalies, with letrozole, as compared to clomiphene, the cumulative ovulation rate was higher. Clomiphene was associated with more numbers of episodes of hot flushes while letrozole was associated with fatigue and dizziness. Rates of other adverse effects were almost similar between these 2 groups. A significant difference in the follicular and endometrial development was evident between these 2 groups. Conclusion: Treatment with Injection of HPE with 2 ovulation induction drugs, Letrozole & Clomiphene Citrate - as compared to clomiphene, letrozole - an aromatase inhibitor, was associated with higher live-birth and ovulation rates in infertile women. The results of the study demonstrated that letrozole is non inferior to clomiphene citrate in the maintenance of endometrial thickness." @default.
• W4367338083 created "2023-04-30" @default.
• W4367338083 creator A5005478401 @default.
• W4367338083 date "2022-02-24" @default.
• W4367338083 modified "2023-10-18" @default.
• W4367338083 title "A Study of Comparison of Effectiveness of Letrozole (5mg) Versus Clomiphene Citrate (100 Mg) by Using Injection Human Placental Extract (HPE) for Ovulation Induction among Infertile Women" @default.
• W4367338083 doi "https://doi.org/10.23880/oajg-16000230" @default.
• W4367338083 hasPublicationYear "2022" @default.
• W4367338083 type Work @default.
• W4367338083 citedByCount "0" @default.
• W4367338083 crossrefType "journal-article" @default.
• W4367338083 hasAuthorship W4367338083A5005478401 @default.
• W4367338083 hasBestOaLocation W43673380831 @default.
• W4367338083 hasConcept C121608353 @default.
• W4367338083 hasConcept C126322002 @default.
• W4367338083 hasConcept C134018914 @default.
• W4367338083 hasConcept C16685009 @default.
• W4367338083 hasConcept C2776166826 @default.
• W4367338083 hasConcept C2777391703 @default.
• W4367338083 hasConcept C2777688143 @default.
• W4367338083 hasConcept C2777702977 @default.
• W4367338083 hasConcept C2778812593 @default.
• W4367338083 hasConcept C2779234561 @default.
• W4367338083 hasConcept C2780853582 @default.
• W4367338083 hasConcept C2781230225 @default.
• W4367338083 hasConcept C29456083 @default.
• W4367338083 hasConcept C3018442814 @default.
• W4367338083 hasConcept C530470458 @default.
• W4367338083 hasConcept C54355233 @default.
• W4367338083 hasConcept C555293320 @default.
• W4367338083 hasConcept C71315377 @default.
• W4367338083 hasConcept C71924100 @default.
• W4367338083 hasConcept C86803240 @default.
• W4367338083 hasConceptScore W4367338083C121608353 @default.
• W4367338083 hasConceptScore W4367338083C126322002 @default.
• W4367338083 hasConceptScore W4367338083C134018914 @default.
• W4367338083 hasConceptScore W4367338083C16685009 @default.
• W4367338083 hasConceptScore W4367338083C2776166826 @default.
• W4367338083 hasConceptScore W4367338083C2777391703 @default.
• W4367338083 hasConceptScore W4367338083C2777688143 @default.
• W4367338083 hasConceptScore W4367338083C2777702977 @default.
• W4367338083 hasConceptScore W4367338083C2778812593 @default.
• W4367338083 hasConceptScore W4367338083C2779234561 @default.
• W4367338083 hasConceptScore W4367338083C2780853582 @default.
• W4367338083 hasConceptScore W4367338083C2781230225 @default.
• W4367338083 hasConceptScore W4367338083C29456083 @default.
• W4367338083 hasConceptScore W4367338083C3018442814 @default.
• W4367338083 hasConceptScore W4367338083C530470458 @default.
• W4367338083 hasConceptScore W4367338083C54355233 @default.
• W4367338083 hasConceptScore W4367338083C555293320 @default.
• W4367338083 hasConceptScore W4367338083C71315377 @default.
• W4367338083 hasConceptScore W4367338083C71924100 @default.
• W4367338083 hasConceptScore W4367338083C86803240 @default.
• W4367338083 hasIssue "1" @default.
• W4367338083 hasLocation W43673380831 @default.
• W4367338083 hasOpenAccess W4367338083 @default.
• W4367338083 hasPrimaryLocation W43673380831 @default.
• W4367338083 hasRelatedWork W1973495657 @default.
• W4367338083 hasRelatedWork W2067460231 @default.
• W4367338083 hasRelatedWork W2155783617 @default.
• W4367338083 hasRelatedWork W2221098663 @default.
• W4367338083 hasRelatedWork W2301316704 @default.
• W4367338083 hasRelatedWork W2751479028 @default.
• W4367338083 hasRelatedWork W2903615895 @default.
• W4367338083 hasRelatedWork W2968211978 @default.
• W4367338083 hasRelatedWork W2972629184 @default.
• W4367338083 hasRelatedWork W3028872866 @default.
• W4367338083 hasVolume "7" @default.
• W4367338083 isParatext "false" @default.
• W4367338083 isRetracted "false" @default.
• W4367338083 workType "article" @default.